Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma Journal Article
| Authors: | Gish, R. G.; Abou-Alfa, G. K.; Tong, M. J. |
| Article Title: | Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma |
| Abstract: | Hepatocellular carcinoma (HCC) is a major cause of cancer-related morbidity and mortality worldwide. In the United States, HCC is the main cause of death in patients with cirrhosis, and the incidence of this malignancy is on the rise. Because HCC is associated with a particularly poor prognosis, emphasis is placed on surveillance of high-risk patients. Early detection allows a greater chance of diagnosing HCC before it has spread, thus increasing the chances that the patient can be potentially cured with surgical techniques such as resection and transplantation. However, most cases of HCC are not diagnosed until at least some of the cancer has spread or multiple nodules exist. For these patients, treatment options include percutaneous and transarterial ablation, as well as systemic chemotherapy. Systemic therapy is now considered the standard of care for patients with advanced tumors. Traditional treatment was based on cytotoxic chemotherapeutic agents, such as doxorubicin. This approach was associated with minimal benefit and a high rate of toxicity. Recently, targeted agents have proven more effective and safer in this setting. The oral multikinase inhibitor sorafenib is now approved for the treatment of unresectable HCC and is currently the only approved agent for advanced HCC. In order to maximize the benefit of sorafenib and other investigational agents for patients with advanced disease, effective interventions have been designed to mitigate their associated adverse events, such as hand-foot skin reactions and hypertension. |
| Keywords: | cancer survival; antibiotic agent; graft infection; clinical trial; fatigue; neutropenia; pathogenesis; sorafenib; bevacizumab; cisplatin; doxorubicin; erlotinib; placebo; sunitinib; ascites; cancer risk; chemoembolization; diarrhea; drug dose reduction; drug potentiation; drug withdrawal; heart left ventricle failure; hepatitis b; hepatitis c; hypertension; hypophosphatemia; liver cell carcinoma; liver cirrhosis; liver transplantation; nonhuman; bone metastasis; conference paper; nuclear magnetic resonance imaging; lymph node metastasis; cancer incidence; diagnostic accuracy; breast cancer; bone marrow suppression; prevalence; lung cancer; antineoplastic activity; cancer mortality; pneumonia; liver metastasis; heart infarction; colon cancer; cardiotoxicity; thrombosis; glioblastoma; echography; bile leakage; comorbidity; ciprofloxacin; liver resection; sex difference; cancer epidemiology; liver function test; lidocaine; kidney cancer; mitomycin; anthracycline; radiofrequency ablation; hand foot syndrome; wound infection; metronidazole; antibiotic prophylaxis; race difference; heart muscle ischemia; ofloxacin; alpha fetoprotein; hair loss; clobetasol; pregabalin; abscess; geographic distribution; codeine; 1 [4 (3 amino 1h indazol 4 yl)phenyl] 3 (2 fluoro 5 methylphenyl)urea; brivanib; bile duct injury; decompensated liver cirrhosis; graft dysfunction; spiral computer assisted tomography |
| Journal Title: | Gastroenterology & Hepatology |
| Volume: | 6 |
| Issue: | 9 Suppl. 16 |
| ISSN: | 1554-7914 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2010-09-01 |
| Start Page: | 1 |
| End Page: | 13 |
| Language: | English |
| PROVIDER: | scopus |
| PMCID: | PMC3302169 |
| PUBMED: | 22423222 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "Source: Scopus" |
